Literature DB >> 2870906

Inhibition of antipyrine metabolite formation. Steady state studies with cimetidine and metyrapone in rats.

P N Shaw, J Tseti, S Warburton, A Adedoyin, J B Houston.   

Abstract

Antipyrine metabolite kinetics have been characterized in rats receiving an intravenous infusion of either saline, cimetidine, or metyrapone. 14CO2 exhalation rate-time profiles following [N-methyl-14C] antipyrine administration demonstrate that, when either cimetidine or metyrapone is maintained at a steady state plasma concentration, a constant degree of inhibition is evident. Under the conditions imposed in this in vivo study, the inhibitory potency of metyrapone is approximately 6 times that observed with cimetidine. Rate constants for the formation of 4-hydroxy-, 3-hydroxymethyl-, and norantipyrine have been calculated using breath and urinary metabolite data under the steady state inhibitory states. Metyrapone nonselectively inhibits the formation of all three oxidative metabolites by approximately one-third. Cimetidine inhibition is selective where rates of 3-methyl-hydroxylation and N-demethylation are reduced by 50% yet 4-hydroxylation is unaffected. The value of assessing inhibitory responses under steady state conditions is discussed and the nonlinear nature of the kinetics of inhibition, when a single bolus dose of inhibitor is used, is illustrated by means of computer simulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870906

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles.

Authors:  P N Shaw; J B Houston
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

2.  The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex.

Authors:  P N Patsalos; W T Abed; M S Alavijeh; M T O'Connell
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.